IL138626A0 - Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily - Google Patents

Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily

Info

Publication number
IL138626A0
IL138626A0 IL13862699A IL13862699A IL138626A0 IL 138626 A0 IL138626 A0 IL 138626A0 IL 13862699 A IL13862699 A IL 13862699A IL 13862699 A IL13862699 A IL 13862699A IL 138626 A0 IL138626 A0 IL 138626A0
Authority
IL
Israel
Prior art keywords
mflint
opg3
polypeptides
therapeutic applications
receptor superfamily
Prior art date
Application number
IL13862699A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL138626A0 publication Critical patent/IL138626A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13862699A 1998-03-30 1999-03-30 Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily IL138626A0 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7985698P 1998-03-30 1998-03-30
US8607498P 1998-05-20 1998-05-20
US9964398P 1998-09-09 1998-09-09
US11257798P 1998-12-17 1998-12-17
US11270398P 1998-12-18 1998-12-18
US11293398P 1998-12-18 1998-12-18
US11340798P 1998-12-22 1998-12-22
PCT/US1999/006797 WO1999050413A2 (en) 1998-03-30 1999-03-30 THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY

Publications (1)

Publication Number Publication Date
IL138626A0 true IL138626A0 (en) 2001-10-31

Family

ID=27568394

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13862699A IL138626A0 (en) 1998-03-30 1999-03-30 Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily

Country Status (16)

Country Link
US (1) US20040167074A1 (xx)
JP (1) JP2002512006A (xx)
KR (1) KR20010042364A (xx)
CN (1) CN1303429A (xx)
AU (1) AU3369199A (xx)
BR (1) BR9909328A (xx)
CA (1) CA2324517A1 (xx)
CZ (1) CZ20003433A3 (xx)
EA (1) EA200001004A1 (xx)
HU (1) HUP0102067A2 (xx)
ID (1) ID27820A (xx)
IL (1) IL138626A0 (xx)
NO (1) NO20004873L (xx)
PL (1) PL343847A1 (xx)
TR (1) TR200002824T2 (xx)
WO (1) WO1999050413A2 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003386B1 (en) 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
CA2358508A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Therapeutic applications of flint polypeptides
DE60036199T2 (de) * 1999-03-30 2008-05-21 Eli Lilly And Co., Indianapolis Proteaseresistente flint-analoge
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
JP2003506088A (ja) 1999-08-04 2003-02-18 アムジェン インコーポレーテッド ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ
WO2001018041A2 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
WO2001028582A2 (en) * 1999-10-20 2001-04-26 Eli Lilly And Company Therapeutic applications of flint polypeptides
WO2001042463A1 (en) * 1999-12-07 2001-06-14 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
AU2001286688A1 (en) * 2000-08-25 2002-03-13 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
WO2002066050A1 (fr) * 2001-02-23 2002-08-29 Takeda Chemical Industries, Ltd. Inhibiteurs de caspase 3
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
WO2006072137A1 (en) * 2005-01-07 2006-07-13 Northern Sydney And Central Coast Area Health Service Treatment for autoimmune and inflammatory conditions
ES2420582T3 (es) 2006-12-28 2013-08-26 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102671186B (zh) * 2011-09-19 2014-08-06 上海市肿瘤研究所 促造血的药物组合物及其应用
EP3150224B1 (en) 2012-07-18 2018-12-26 Apogenix AG Inhibitors of the cd95 signaling pathway for treatment of mds
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
TWI623321B (zh) 2015-12-18 2018-05-11 Talengen Institute Of Life Sciences Co Ltd Method for preventing and treating cervical erosion
KR20220002336A (ko) 2019-03-29 2022-01-06 미스트 쎄라퓨틱스, 엘엘씨 T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003386B1 (en) * 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
CA2299619A1 (en) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
IL134578A0 (en) * 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2

Also Published As

Publication number Publication date
WO1999050413A2 (en) 1999-10-07
BR9909328A (pt) 2000-12-12
WO1999050413A3 (en) 1999-12-02
JP2002512006A (ja) 2002-04-23
US20040167074A1 (en) 2004-08-26
CZ20003433A3 (cs) 2001-10-17
NO20004873L (no) 2000-11-24
KR20010042364A (ko) 2001-05-25
CA2324517A1 (en) 1999-10-07
ID27820A (id) 2001-04-26
HUP0102067A2 (hu) 2001-10-28
CN1303429A (zh) 2001-07-11
NO20004873D0 (no) 2000-09-28
EA200001004A1 (ru) 2001-06-25
TR200002824T2 (tr) 2000-12-21
PL343847A1 (en) 2001-09-10
AU3369199A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
IL138626A0 (en) Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily
AU5923398A (en) Polynucleotides and polypeptides encoding receptors
PT1090128E (pt) Polipéptidos dependentes da vitamina k modificados
AU6535098A (en) Zcytor7 cytokine receptor
EP1041888A4 (en) ANTIRETROVIRAL IMMUNOGENS, PREPARATION AND USE THEREOF
HK1030036A1 (en) Nozzle adjusting mechanism
AU8673198A (en) Il-8 receptor antagonists
EP1023437A4 (en) KINASE RECEPTOR, BIN1
AU5733898A (en) Member of the hematopoietin receptor superfamily
GB2331184B (en) Thermally responsive switch
IL133920A0 (en) Trail receptor
EP0929218A4 (en) R2Y RECEPTOR ANTAGONISTS
AU2001295412A1 (en) A novel polypeptide, a human cytokine receptor 10.67 and the polynucleotide encoding the polypeptide
EP0870198A4 (en) RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR
AU6435098A (en) Il-8 receptor antagonists
AU3739400A (en) Flint polypeptide analogs
PL337722A1 (en) Novel combination antiasthmatic drugs
EP0973800A4 (en) NEW RECEIVER
GB9726539D0 (en) Polypeptides, polynucleotides and uses thereof
AU4411699A (en) Interferon receptor hkaef92
EP1043333A4 (en) NOVEL POLYPEPTIDES, cDNA ENCODING SAID POLYPEPTIDES, AND USE THEREOF
EP1005489A4 (en) NEW POLYPEPTIDES FROM THE GROWTH FACTOR FAMILY
AU6826498A (en) Endotholin receptor antagonists
GB9719150D0 (en) Interfacing stones
GB2318456B (en) Safety switch